Brief: Galderma - Nemolizumab Data Demonstrate Benefits For Children Moderate-To-Severe Atopic Dermatitis

Galderma AG

30/03/2026 06:19

March 30 (Reuters) - Galderma Group AGGALD.S said on Saturday:

AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis

A 75% improvement in the Eczema Area and Severity Index score was observed as early as Week 4, with 69-73% of patients achieving it by Week 161

A 75% improvement in the Eczema Area and Severity Index score was observed as early as Week 4, with 69-73% of patients achieving it by Week 16

 Further company coverage: [GALD.S]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))